SciELO - Scientific Electronic Library Online

 
vol.104 issue3Recommendations pertaining to the use of viral vaccines: Influenza 2014 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

SAMJ: South African Medical Journal

On-line version ISSN 2078-5135
Print version ISSN 0256-9574

Abstract

CONRADIE, F et al. Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. SAMJ, S. Afr. med. j. [online]. 2014, vol.104, n.3, pp.164-166. ISSN 2078-5135.

While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License